



## OPEN ACCESS

## EDITED BY

Taxiarchis Botsis,  
Johns Hopkins University, United States

## REVIEWED BY

Cristiano Matos,  
Escola Superior de Tecnologia da Saúde  
de Coimbra, ESTeSC-IPC, Portugal

## \*CORRESPONDENCE

Andrew Bate,  
✉ andrew.x.bate@gsk.com

RECEIVED 21 June 2023

ACCEPTED 30 June 2023

PUBLISHED 04 December 2023

## CITATION

Painter JL, Kassekert R and Bate A (2023),  
Corrigendum: An industry perspective on  
the use of machine learning in drug and  
vaccine safety.  
*Front. Drug Saf. Regul.* 3:1244115.  
doi: 10.3389/fdsfr.2023.1244115

## COPYRIGHT

© 2023 Painter, Kassekert and Bate. This  
is an open-access article distributed  
under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction in  
other forums is permitted, provided the  
original author(s) and the copyright  
owner(s) are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# Corrigendum: An industry perspective on the use of machine learning in drug and vaccine safety

Jeffery L. Painter<sup>1</sup>, Raymond Kassekert<sup>2</sup> and Andrew Bate<sup>3,4\*</sup>

<sup>1</sup>GlaxoSmithKline, Global Safety, Durham, NC, United States, <sup>2</sup>GlaxoSmithKline, Global Safety, Upper Providence, PA, United States, <sup>3</sup>GlaxoSmithKline, Global Safety, Brentford, Middlesex, United Kingdom, <sup>4</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom

## KEYWORDS

pharmacovigilance, machine learning-ML, drug safety, vaccines safety, artificial intelligence

## A Corrigendum on

### An industry perspective on the use of machine learning in drug and vaccine safety

by Painter JL, Kassekert R and Bate A (2023). *Front. Drug. Saf. Regul.* 3:1110498. doi: [10.3389/fdsfr.2023.1110498](https://doi.org/10.3389/fdsfr.2023.1110498)

In the published article, there was an error in [Figure 1](#) as published. The figure failed to include the details on the individual node references. The corrected [Figure 1](#) and its caption appear below.


In the published article, [Table 1](#) was mistakenly not included in the publication. The missing material appears below.

In the published article, [Table 1](#) should now be updated as [Table 2](#) and any associated references to [Table 1](#) should refer to [Table 2](#), with no changes to its legend or content.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



**FIGURE 1**  
 The benefits of robotic process automation (RPA). Additional details are found in [Table 1](#).

**TABLE 1** Details on the benefits of robotic process automation (RPA).

Node	Phase	Benefit	Description
<b>Expected Benefits</b>			
A	Before RPA	Enforcement of organizational policies	Automation defaults to observing organizational policies in a systematic way
B	Introduction of RPA	Improvement in time efficiency	Reduction in time for case processing and booking
D	Introduction of RPA	Reduction of manual tasks and workload	Reduction of repetitive, mundane, tedious manual tasks
E	Introduction of RPA	Improvement in data accuracy	Automate data processing in systematic way. Decrease potential errors and mistakes in safety case review and processing
F	RPA in Systematic Use	Decrease in compliance risk	Timelier fulfillment of compliance and audit requirements for regulatory bodies
G	RPA in Systematic Use	Improvement in human resource utilization	Better utilization of staff, focus on cases which require human intervention
J	RPA in Systematic Use	Return on investment	Increase capability for high volume case processing without increasing staff
K	RPA in Systematic Use	Increase in operational reliability	Allows the organization to operate reliably, even when faced with unexpected challenges
<b>Unexpected Benefits</b>			
C	Introduction of RPA	Improved employee participation	Staff is relieved from repetitive tasks and able to focus on improving overall business processes and decision making
H	RPA in Systematic Use	Improvement in transparency, visibility and better understanding of processes	Business processes and business rules are judiciously executed, processes are documented and explainable to stakeholders
I	RPA in Systematic Use	Improvement in job satisfaction	Empower staff to focus on the most important tasks which lead to better job fulfillment